Angela Rice
Family Medicine · Manchester, KYNPI 1134231822
Payments from drug & device makers
Across 341 payments — averaging $14.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$932
- AbbVie$878
- Lilly USA, LLC$546
- AstraZeneca$511
- Merck$321
- GSK$289
- plus $2K from 23 others
What the payments were for
- Food & beverage$5,03099%
- Education$301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 65 | $932 |
| AbbVie(2 entities) | 57 | $878 |
| Lilly USA, LLC | 54 | $546 |
| AstraZeneca | 27 | $511 |
| Merck | 19 | $321 |
| GSK | 21 | $289 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $188 |
| Medtronic | 8 | $165 |
| Ardelyx, Inc. | 9 | $156 |
| Bayer | 7 | $136 |
| Boehringer Ingelheim | 7 | $107 |
| Amgen | 4 | $103 |
| Dexcom, Inc. | 6 | $101 |
| Sunovion Pharmaceuticals Inc. | 5 | $75 |
| Amarin Pharma, Inc. | 5 | $72 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $65 |
| Phathom Pharmaceuticals, Inc. | 9 | $64 |
| Novartis | 3 | $48 |
| Astellas Pharma US Inc | 3 | $44 |
| Pfizer | 3 | $43 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| Sanofi-aventis U.S. LLC | 2 | $30 |
| Radius Health, Inc. | 2 | $29 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $29 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Verona Pharma, Inc. | 1 | $22 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Exact Sciences | 1 | $15 |
| Johnson & Johnson | 1 | $11 |
How this compares
$5,061 in reported general payments places this provider in the 85th percentile of 1,559 family medicine providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 126 | $127,437 |
| OzempicSemaglutide | 115 | $125,745 |
| EliquisApixaban | 94 | $86,652 |
| LinzessLinaclotide | 140 | $85,768 |
| JardianceEmpagliflozin | 81 | $84,477 |
| TrulicityDulaglutide | 60 | $75,268 |
| CreonLipase/Protease/Amylase | 59 | $49,385 |
| VraylarCariprazine Hcl | 34 | $47,498 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 57 | $38,553 |
| MounjaroTirzepatide | 30 | $30,504 |
| Aimovig AutoinjectorErenumab-Aooe | 27 | $25,586 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 41 | $25,012 |
| RexultiBrexpiprazole | 13 | $18,626 |
| Ondansetron Hcl | 157 | $18,033 |
| FarxigaDapagliflozin Propanediol | 25 | $17,335 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon, Vraylar, Synthroid | $878 | $185,818312 claims |
| MerckJanuvia, Janumet Xr, Janumet | $321 | $154,693156 claims |
| Novo NordiskOzempic | $932 | $125,745115 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $546 | $109,968110 claims |
| PfizerEliquis | $43 | $86,65294 claims |
| Boehringer IngelheimJardiance | $107 | $84,47781 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $289 | $45,18574 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $511 | $42,34766 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $36 | $18,62613 claims |
| NovartisEntresto | $48 | $12,33517 claims |
| Astellas Pharma US IncMyrbetriq | $44 | $9,19715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in Manchester
- Brian SmithVersailles$7.7M
- Barbara Fleming-PhillipsLexington$1.4M
- Christopher RhyneLouisville$1M
- Kruti PatelBurlington$463K
- Michael LovelaceLouisville$244K
- John RichardLexington$226K
- Diego MastronardiBowling Green$196K
- James TurnboPaducah$124K
- Eleida Tur OlivaLexington$113K
- Jeffrey GreenParis$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.